MARKET

PRTA

PRTA

Prothena Corp
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.51
+0.52
+4.73%
Closed 17:10 04/02 EDT
OPEN
10.97
PREV CLOSE
10.99
HIGH
11.62
LOW
10.51
VOLUME
233.08K
TURNOVER
--
52 WEEK HIGH
17.63
52 WEEK LOW
6.71
MARKET CAP
459.38M
P/E (TTM)
-5.9098
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 8 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average PRTA stock price target is 14.50 with a high estimate of 19.00 and a low estimate of 13.00.

EPS

PRTA News

More
  • Baseline Data from Phase 2 PASADENA Study of Prasinezumab (PRX002/RG7935) in Parkinsons Disease to be Presented at AAT-AD/PD
  • GlobeNewswire · 2d ago
  • Prothena Reports Baseline Data From Phase 2 PASADENA Study Of Prasinezumab In Patients With Early Parkinson's Disease Will Be Presented By Roche
  • Benzinga · 2d ago
  • Prothena (PRTA) Down 24.8% Since Last Earnings Report: Can It Rebound?
  • Zacks · 03/13 16:30
  • Prothena Announces Appointment of Brandon Smith as Chief Business Officer
  • GlobeNewswire · 03/03 21:05

Industry

Biotechnology & Medical Research
+3.33%
Pharmaceuticals & Medical Research
+2.80%

Hot Stocks

Symbol
Price
%Change

About PRTA

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004). The Company has generated monoclonal antibodies that selectively bind to amyloidogenic (diseased) forms of the Transthyretin (TTR)-mediated amyloidosis (ATTR) protein. The Company's pipeline also includes late discovery-stage programs for which the Company is testing the efficacy of antibodies in preclinical models of diseases related to amyloid or cell adhesion.
More

Webull offers kinds of Prothena Corporation PLC stock information, including NASDAQ:PRTA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRTA stock news, and many more online research tools to help you make informed decisions.